Phaseline

Companies › Scancell

Scancell: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SCIB1
DNA vaccine encoding modified gp100 and TRP-2 to stimulate anti-tumor immunity
–Phase 2Malignant MelanomaJan 2027
Modi-1 Moditope
Personalized neoantigen vaccine
–Phase 1Triple Negative Breast CancerJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04079166SCIB1Phase 2Malignant MelanomaOncologyJan 2027
NCT04079166SCIB1Phase 2Malignant MelanomaOncologyJan 2027
NCT05329532Modi-1 ModitopePhase 1Triple Negative Breast CancerOncologyJul 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Allotera Therapeutics Diakonos Oncology Beijing Yongtai Ruike Biotechnology Company Imbioray (Hangzhou) Biomedicine ImmVira Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.